AU2001257903A1 - Method for treatment of neurodegenerative diseases - Google Patents
Method for treatment of neurodegenerative diseasesInfo
- Publication number
- AU2001257903A1 AU2001257903A1 AU2001257903A AU5790301A AU2001257903A1 AU 2001257903 A1 AU2001257903 A1 AU 2001257903A1 AU 2001257903 A AU2001257903 A AU 2001257903A AU 5790301 A AU5790301 A AU 5790301A AU 2001257903 A1 AU2001257903 A1 AU 2001257903A1
- Authority
- AU
- Australia
- Prior art keywords
- treatment
- neurodegenerative diseases
- neurodegenerative
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19110900P | 2000-03-22 | 2000-03-22 | |
US60191109 | 2000-03-22 | ||
PCT/US2000/020138 WO2001071351A1 (en) | 2000-03-22 | 2000-07-25 | Method for treatment of neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001257903A1 true AU2001257903A1 (en) | 2001-10-03 |
Family
ID=22704180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001257903A Abandoned AU2001257903A1 (en) | 2000-03-22 | 2000-07-25 | Method for treatment of neurodegenerative diseases |
Country Status (3)
Country | Link |
---|---|
US (1) | US20020015941A1 (en) |
AU (1) | AU2001257903A1 (en) |
WO (1) | WO2001071351A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02009756A (en) * | 2000-04-03 | 2003-06-17 | Bristol Myers Squibb Co | Isolation of functionally active gamma secretase protein complex and methods for detection of activity and inhibitors thereof. |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
AU2004212944B2 (en) | 2003-02-14 | 2008-08-21 | Children's Hospital & Research Center At Oakland | Lipophilic drug delivery vehicle and methods of use thereof |
US20060188938A1 (en) * | 2005-01-07 | 2006-08-24 | Mullan Michael J | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds |
WO2007064972A2 (en) | 2005-11-30 | 2007-06-07 | Abbott Laboratories | Monoclonal antibodies against amyloid beta protein and uses thereof |
ES2524984T3 (en) | 2005-11-30 | 2014-12-16 | Abbvie Inc. | Anti-globulomer antibodies to? Antigen-binding portions thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies, compositions comprising said antibodies, uses of said antibodies, and methods for using said antibodies |
WO2007103683A2 (en) * | 2006-03-01 | 2007-09-13 | Roskamp Research Llc | Compounds for inhibiting beta-amyloid production |
GB0606015D0 (en) | 2006-03-28 | 2006-05-03 | Merck Sharp & Dohme | therapeutic agents |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US20100119599A1 (en) * | 2006-12-08 | 2010-05-13 | Archer Pharmaceuticals, Inc. | Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid production |
JP2010518064A (en) | 2007-02-12 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | Piperazine derivatives for the treatment of AD and related conditions |
US8895004B2 (en) * | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
US8268796B2 (en) | 2008-06-27 | 2012-09-18 | Children's Hospital & Research Center At Oakland | Lipophilic nucleic acid delivery vehicle and methods of use thereof |
WO2010071741A1 (en) | 2008-12-16 | 2010-06-24 | Merck Sharp & Dohme Corp. | Triazole derivatives for treatment of alzheimer's disease |
JP2013523182A (en) | 2010-04-15 | 2013-06-17 | アボット・ラボラトリーズ | Amyloid beta-binding protein |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
GB201212334D0 (en) | 2012-07-11 | 2012-08-22 | Warwick The | Therapeutic targets for alzheimers disease |
AU2014101153A4 (en) * | 2014-01-03 | 2014-10-23 | Macau University Of Science And Technology | A Group of Alkaloids, the Novel Autophagic Enhancers for Treatment of Cancers and Neurodegenerative Conditions Thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5932417A (en) * | 1996-10-15 | 1999-08-03 | The Regents Of The University Of California | Method of screening compounds for controlling capacitative calcium ion entry into mammalian cells |
-
2000
- 2000-07-25 WO PCT/US2000/020138 patent/WO2001071351A1/en active Application Filing
- 2000-07-25 AU AU2001257903A patent/AU2001257903A1/en not_active Abandoned
-
2001
- 2001-03-22 US US09/814,179 patent/US20020015941A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20020015941A1 (en) | 2002-02-07 |
WO2001071351A1 (en) | 2001-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002332430A1 (en) | Methods of treating neuropilin-mediated diseases | |
AU2002243231A1 (en) | Method of treating autoimmune diseases | |
AU1294401A (en) | Methods for treating fibroproliferative diseases | |
HUP0203803A3 (en) | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | |
AU2001257903A1 (en) | Method for treatment of neurodegenerative diseases | |
AU2001288271A1 (en) | Methods for treating inflammatory diseases | |
AU2002210385A1 (en) | Furazanyl-triazole derivates for the treatment of diseases | |
AU2001286983A1 (en) | Method of treatment | |
AU2001285747A1 (en) | Method for the treatment of tobacco | |
AU2003259833A1 (en) | Methods of treating neurodegenerative diseases | |
AU2002229986A1 (en) | Method of treating neurological diseases | |
AU4215499A (en) | Treatment of neurodegenerative diseases | |
AU3004000A (en) | Methods for the treatment of apolipoprotein e related diseases | |
AU2001262177A1 (en) | Method of treatment | |
AU2002225327A1 (en) | Apparatus for aesthetic treatment | |
AU2003291730A1 (en) | Methods and compositions for treating neurodegenerative diseases | |
AUPR536401A0 (en) | Method for treatment of waste water | |
AUPR731901A0 (en) | Method of treatment | |
AU1405001A (en) | Treatment of diseases | |
AU5854799A (en) | Novel treatment of neurodegenerative diseases | |
AU4598400A (en) | Method of treatment | |
AU2001253560A1 (en) | Methods of treatment | |
AU2001262252A1 (en) | Means for treating attacks of auto-immune diseases | |
AUPR213000A0 (en) | Method of treatment | |
AUPQ949500A0 (en) | Method of treatment |